News
Merck to Acquire Verona Pharma for $10 Billion to Boost COPD Drug Portfolio
Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence on its blockbuster cancer drug Keytruda.
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...
A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in ...
Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...
Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...
U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of ...
This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback